Press Releases on August 8, 2024 - EIN Presswire - Press Release Distribution Service

Published on August 8, 2024 - 20:05 GMT

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

- Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with hematologic malignancies including acute myelogenous leukemia (AML) for INB-100 at the European Hematology Association (EHA) 2024 Congress - Continues …

Distribution channels: Business & Economy, Technology ...

Published on August 8, 2024 - 20:05 GMT

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Management Hosting …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Byrna Technologies Sets Upcoming Investor Conference Schedule

ANDOVER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a technology company, specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, is …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on August 8, 2024 - 20:05 GMT

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Genomic Medicine Summit in …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on August 8, 2024 - 20:05 GMT

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results

CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Seer Reports Second Quarter 2024 Financial Results

REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Phunware Reports Second Quarter 2024 Financial Results

AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), the mobile experience platform that guides your customers through every step of their journey with you, announces its financial results for the …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance

─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin ─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on August 8, 2024 - 20:05 GMT

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 Evalstotug (CAB-CTLA-4 antibody) demonstrated a …

Distribution channels: Business & Economy, Technology ...

Published on August 8, 2024 - 20:05 GMT

PDF Solutions® Reports Second Quarter 2024 Results

SANTA CLARA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its second quarter ended …

Distribution channels: Business & Economy, Culture, Society & Lifestyle ...

Published on August 8, 2024 - 20:05 GMT

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the …

Distribution channels: Companies, Technology ...

Published on August 8, 2024 - 20:05 GMT

Codexis Reports Second Quarter 2024 Financial Results

Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on August 8, 2024 - 20:05 GMT

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Century Aluminum Company Reports Second Quarter 2024 Results

CHICAGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its second quarter 2024 results. Business Highlights Net sales of $560.8 million Realized LME aluminum price of $2,288/MT in second quarter is up $98/MT from …

Distribution channels: Business & Economy, Mining Industry ...

Published on August 8, 2024 - 20:05 GMT

Potbelly Corporation Reports Results for Second Fiscal Quarter 2024

22 additional new franchise shop commitments in the second quarter 9 shop openings year-to-date through August 8th CHICAGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood …

Distribution channels: Business & Economy, Food & Beverage Industry ...

Published on August 8, 2024 - 20:05 GMT

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study …

Distribution channels: Business & Economy, Technology ...

Published on August 8, 2024 - 20:05 GMT

Synaptics Reports Fourth Quarter and Full Year Fiscal 2024 Results

Q4’24 Financial Results and Recent Business Highlights Revenue of $247.4 million GAAP gross margin of 45.8 percent Non-GAAP gross margin of 53.4 percent GAAP diluted earnings per share of $5.22 Non-GAAP diluted earnings per share of $0.64 SAN JOSE, Calif …

Distribution channels: Business & Economy, Technology ...

Published on August 8, 2024 - 20:05 GMT

The Joint Corp. Reports Second Quarter 2024 Financial Results

- Grew Q2 2024 Revenue 3%, System-wide Sales 8% and System-wide Comp Sales 2% vs. Q2 2023 - - Increased Clinic Count to 960 at June 30, 2024 - SCOTTSDALE, Ariz., Aug. 08, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager …

Distribution channels:

Published on August 8, 2024 - 20:05 GMT

Profound Medical Announces Second Quarter 2024 Financial Results

TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...